CHGB and Alzheimer disease: Similar to our peptidomics results, lower CSF levels of SCG1 protein have been reported for ALS, Parkinson’s disease and AD patients and were explained with neuronal loss or reduction in protein secretion (Park et al, 2020; Zhu et al, 2019).